Lancet oncol: avelumab alone or combined with PLD can significantly prolong the survival prognosis of platinum-resistant/refractory ovarian cancer

Most patients with ovarian cancer will relapse after first-line platinum chemotherapy, and eventually develop platinum-resistant or platinum-refractory ovarian cancer
.
This article reports the efficacy of avelumab alone or avelumab combined with pegylated liposomal adriamycin (PLD) compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer

JAVELIN Ovarian 200 is an open-label, parallel-group, three-arm, randomized phase 3 trial conducted in 149 hospitals/cancer treatment centers in 24 countries.
It recruits 18-year-old epithelial cell ovarian cancer, fallopian tube cancer or Patients with peritoneal cancer who require no more than 3 previous treatments have an ECOG performance status of 0 or 1
.
The test patients were randomly divided into three groups 1:1:1, and received avelumab (10 mg/kg·2 weeks), avelumab+PLD (40 mg/m2·4 weeks) or PLD treatment, and based on their sensitivity to platinum Stratified by sex, previous anti-cancer protocols and tumor volume

Progression-free survival and overall survival

From January 5, 2016 to May 16, 2017, a total of 566 patients were recruited and randomly divided into three groups: 188 in the combined group, 190 in the PLD group, and 188 in the avelumab group
.
As of September 19, 2018, the median follow-up times of overall survival in the combination group, PLD group and avelumab group were 18.

Treatment-related adverse events

The most common treatment-related adverse events of grade 3 and above are palmoplantar erythema paresthesia syndrome (combination group vs PLD group vs avelumab group: vs 10% vs 5% vs 0), rash (6% vs 2% vs 0) ), fatigue (5% vs 2% vs 0), stomatitis (5% vs 3% vs 0), anemia (3% vs 5% vs 2%), neutropenia (5% vs 5% vs 0) and decreased neutrophil count (5% vs 4% vs 0)
.
There were 32 (18%), 19 (11%) and 14 (7%) severe treatment-related adverse events in the combination group, PLD group and avelumab group, respectively

All in all, compared with PLD alone, avelumab combined with PLD or avelumab alone can significantly prolong the progression-free survival and overall survival of platinum-resistant or refractory ovarian cancer, fallopian tube cancer, and peritoneal cancer

Eric Pujade-Lauraine, et al.